Valya was born with a very harsh congenital disease – juvenile rheumatoid arthritis, joint-affecting form. She also suffers with anemia of mixed origin, steroid-induced diabetes, congenital heart disease, and common variable immunodeficiency (CVID).
Because of having been treated with hormonal agents, Valya lags behind in her physical development. She’s 13, but she looks like as if she was a 7-year-old child with a height of 119 cm. Valya loves studying at school, drawing, and taking care of kittens and puppies. She keeps saying that when she grows up, she will become a veterinarian and will cure all cats and dogs from their diseases.
Valya takes a big interest in life. Like all kids, she likes to dream and play. Her joyful rolling laughter attracts other kids, she has a lot of friends who love her. The girl has 2 elder sisters and a brother suffering with a serious disease since his childhood (he is disabled).
From 2006 to 2012 Valya was receiving prescription drug Infliximab. A complete resistance to Infliximab developed by 2012, so the girl was prescribed with Etanercept. The treatment with the new drug lasted for 1.5 years and it was moderately effective. Unfortunately, the disease has been progressing in the last half of the year. Currently, all symptoms of polyarthritis have manifested. As a result, therapy with Etanercept was cancelled and the girl was prescribed with Tocilizumab (200 mg - 1 time in 2 weeks). There is a positive clinical dynamics after the first administration of the medicine. The cost of 1 pack of the drug is 28,800 rubles, 2 packs are needed monthly. Valya will be released home soon, and while her mother will be passing through a routine in order to make the Ministry of Health provide Valya with the new medicine, it is necessary to buy 4 packs of it (the total cost is 115,200 rubles).